Information  X 
Enter a valid email address

IQ-AI Limited (IQAI)

  Print      Mail a friend

Friday 28 February, 2020

IQ-AI Limited

Total Voting Rights

RNS Number : 5389E
IQ-AI Limited
28 February 2020
 

 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Total Voting Rights

 

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that it has 145,955,982 ordinary shares of £0.01 in issue, each share carrying the right to one vote. The Company does not hold any ordinary shares in treasury.

 

The above figure of 145,955,982 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

The Directors of the issuer accept responsibility for the contents of this announcement.

 

--ENDS-

 

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

About IQ-AI Ltd 

IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information. 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRKKFBNNBKDCBB

a d v e r t i s e m e n t